Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis

BACKGROUND & AIMS: Pharmacologic agents targeting bile acid signaling show promise for treating nonalcoholic steatohepatitis (NASH). However, clinical findings suggest that new treatment strategies with enhanced therapeutic efficacy and minimized undesired effects are needed. This preclinical st...

Descripción completa

Detalles Bibliográficos
Autores principales: Matye, David J., Wang, Huaiwen, Luo, Wenyi, Sharp, Rachel R., Chen, Cheng, Gu, Lijie, Jones, Kenneth L., Ding, Wen-Xing, Friedman, Jacob E., Li, Tiangang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346663/
https://www.ncbi.nlm.nih.gov/pubmed/33965587
http://dx.doi.org/10.1016/j.jcmgh.2021.04.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346663/
https://www.ncbi.nlm.nih.gov/pubmed/33965587
http://dx.doi.org/10.1016/j.jcmgh.2021.04.013

Ejemplares similares